Koyfin Home > Directory > Health Care > Revance Therapeutics > Cash Flow from Operations

Revance Therapeutics Cash Flow from Operations Chart (RVNC)

Revance Therapeutics annual/quarterly Cash Flow from Operations from 2012 to 2020. Cash flow from operating activities (CFO) is an accounting item that indicates the amount of money a company brings in from ongoing, regular business activities, such as manufacturing and selling goods or providing a service. Cash flow from operating activities does not include long-term capital or investment costs.
  • Revance Therapeutics Cash Flow from Operations for the quarter ending June 06, 2020 was $-17m a -85.61% increase of 15m year over year
  • Revance Therapeutics Cash Flow from Operations for the last 12 months ending June 06, 2020 was $-126m a 17.60% decrease of -22m year over year
  • Revance Therapeutics Annual Cash Flow from Operations for 2019 was $-106m a 1.80% decrease of -2m from 2018
  • Revance Therapeutics Annual Cash Flow from Operations for 2018 was $-104m a 8.54% decrease of -9m from 2017
  • Revance Therapeutics Annual Cash Flow from Operations for 2017 was $-95m a 37.25% decrease of -36m from 2016
Other Cash Flow Metrics:
  • Revance Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-14m a -14.44% increase of 2m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Cash Flow from Operations Data

06/2020$-17m
03/2020$-43m
12/2019$-34m
09/2019$-32m
06/2019$-29m
03/2019$-11m
12/2018$-31m
09/2018$-25m
06/2018$-37m
03/2018$-11m

Annual RVNC Cash Flow from Operations Data

2019$-106m
2018$-104m
2017$-95m
2016$-60m
2015$-56m
2014$-55m
2013$-48m
2012$-39m
2011$-28m